Lomond Therapeutics Holdings, Inc.
Clinical trials sponsored by Lomond Therapeutics Holdings, Inc., explained in plain language.
-
New hope for hard-to-treat blood cancers: experimental drug enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called ZE50-0134 in about 66 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or certain low-grade lymphomas that have returned or not responded to prior therapies. The main goals are to check the drug's safety and how …
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated May 17, 2026 05:05 UTC
-
New hope for leukemia patients: experimental drug targets resistant cancers
Disease control Recruiting nowThis early-stage study tests a new drug, ZE46-0134, in adults with a hard-to-treat form of acute myeloid leukemia (AML) that has come back or not responded to standard treatment. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 150 parti…
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC